<DOC>
	<DOCNO>NCT00005589</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . It yet know combination chemotherapy plus peripheral stem cell transplantation effective without rituximab non-Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study give combination chemotherapy peripheral stem cell transplantation together rituximab see well work compare combination chemotherapy peripheral stem cell transplantation alone treat patient relapse non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With Without Rituximab Treating Patients With Relapsed Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect vivo rituximab purge maintenance progression-free survival patient relapse resistant follicular non-Hodgkin 's lymphoma undergoing high-dose chemotherapy . - Determine effect regimen response rate overall survival patient population . - Determine effect vivo purge rituximab molecular remission rate hematopoietic product patient . - Determine safety rituximab transplant setting . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord type remission ( complete vs good partial ) remission ( second v third ) . Patients randomize one four treatment arm . All patient receive induction chemotherapy comprise cyclophosphamide IV 3-4 hour day 0 standard induction chemotherapy regimen . Filgrastim ( G-CSF ) administer subcutaneously daily begin day 1 . Patients randomize receive either vivo rituximab purge purge follow restaging completion induction . For patient receive purging ( arm I II ) , rituximab administer IV weekly 4 week . Peripheral blood stem cell ( PBSC ) collect day 8 12 post induction chemotherapy . Within 4 week PBSC collection , patient receive carmustine IV 2 hour day -6 , etoposide IV 2 hour day -5 -2 , cytarabine IV 5 minute twice daily day -5 -2 , melphalan IV 10-15 minute day -1 . ( Alternatively , high dose cyclophosphamide total body irradiation begin 2-4 week cyclophosphamide standard induction chemotherapy priming also allow . ) PBSC reinfused day 0 . Patients randomize receive either rituximab maintenance observation . For patient receive maintenance ( arm I III ) , rituximab administer IV every 2 month 4 dos begin 30 day PBSC reinfusion . Patients follow 30 day , 3 , 6 , 9 , 12 month PBSC transplant , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 460 patient ( 115 per treatment arm ) accrue study within 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Relapsed resistant follicular nonHodgkin 's lymphoma ( NHL ) No evidence transformation high grade diffuse large Bcell NHL CD20 positive evidence transformation Achievement complete remission ( CR ) good partial remission ( VGPR ) follow reinduction chemotherapy standard regimen Includes patient fail respond firstline chemotherapy achieve CR VGPR proceed directly secondline chemotherapy Platelet count great 100,000/mm^3 induction chemotherapy randomization No CNS involvement PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin normal ALT great 2 time upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN Hepatitis B negative Hepatitis C negative Renal : Creatinine great 2 time ULN BUN great 2 time ULN Cardiovascular : No inadequate cardiac function Pulmonary : No inadequate pulmonary function Other : Not pregnant nursing HIV negative No uncontrolled serious medical condition No malignancy within past 5 year except nonmelanoma skin tumor carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : More 12 month since prior CD20 therapy , include rituximab No prior peripheral blood stem cell transplantation Chemotherapy : See Disease Characteristics No 3 prior chemotherapy regimen NHL Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy great 30 % bone marrow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
</DOC>